VLS — Vita Life Sciences Income Statement
0.000.00%
- AU$98.98m
- AU$70.83m
- AU$79.51m
- 94
- 82
- 54
- 88
Annual income statement for Vita Life Sciences, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | C2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 46.5 | 57.1 | 66.9 | 73.4 | 79.5 |
Cost of Revenue | |||||
Gross Profit | 29.3 | 34.8 | 39.7 | 42.4 | 47.2 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 38.4 | 45.9 | 56.2 | 61.4 | 67.7 |
Operating Profit | 8.13 | 11.2 | 10.6 | 12 | 11.8 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 8.16 | 11.2 | 10.7 | 12.5 | 12.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | 5.86 | 8.25 | 7.34 | 9.08 | 8.78 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 6.09 | 8.29 | 7.08 | 9.08 | 8.78 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 6.09 | 8.29 | 7.08 | 9.08 | 8.78 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.116 | 0.156 | 0.131 | 0.166 | 0.16 |
Dividends per Share |